{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.89","upperLimit":"8.31","value":"4.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"description":"PFS was defined as the time between start of treatment and the first documentation of recurrence, progression, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"MEDIAN","populationDescription":"All-treated population - all participants who received at least 1 dose of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 40 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}